Irofulven - CAS 158440-71-2

Irofulven - CAS 158440-71-2 Catalog number: BADC-00330

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Irofulven is a semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens. Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.

Category
ADCs Cytotoxin
Product Name
Irofulven
CAS
158440-71-2
Catalog Number
BADC-00330
Molecular Formula
C15H18O3
Molecular Weight
246.12
Irofulven

Ordering Information

Catalog Number Size Price Quantity
BADC-00330 5 mg $1490
Inquiry
Description
Irofulven is a semisynthetic sesquiterpene derivative of illudin S, a natural toxin isolated from the fungus Omphalotus illudens. Irofulven alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.
Synonyms
6-hydroxymethylacylfulvene; hydroxymethylacylfulvene; MGI 114; MGI-114; MGI114
IUPAC Name
(5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
Canonical SMILES
CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO
InChI
InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
InChIKey
NICJCIQSJJKZAH-AWEZNQCLSA-N
Mechanism Of Action
MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or "cell suicide." During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.
In Vitro
Cell cycle studies show that irofulven increases the proportion of cells in the S phase. Cisplatin-irofulven and oxaliplatin-irofulven combinations block cells in G1/S and potently induce apoptosis.
In Vivo
Single agent irofulven displayed cytotoxic effects against human colon HT29 cells, human breast cancer cell lines including MCF7, SKBR3, and ZR-75-1, and human ovarian cancer cell lines CAOV3, OVCAR3, and IGROV1, with OVCAR3 being the most sensitive cancer cell line (IC50: 2.4 microM). In all tested cell lines the oxaliplatin-irofulven combination led to clear evidence of synergistic activity. In HT29 and HT29/IF2, the sequence oxaliplatin followed by irofulven appears to be the most effective whereas in MCF7 cells, irofulven given prior to or simultaneously with oxaliplatin is more effective than the other schedule. The combination displays additive activity toward CAOV3 ovarian cells when irofulven was administered prior to or simultaneously with oxaliplatin and partially synergistic when oxaliplatin was followed by irofulven. In most of the cell lines, the sequence oxaliplatin followed by irofulven appears to be the most effective as compared to other schedules. A combination of irofulven with cisplatin has the same efficacy as with oxaliplatin for the same cell lines.
Clinical Trial Information
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT00033735Pancreatic CancerPhase 32012-12-24Eisai Inc.Completed
NCT00005968Melanoma (Skin)Phase 22013-05-30University of Colorado, DenverCompleted
NCT00374660Liver CancerPhase 12015-07-01Eisai Inc.Unknown Verified June 2015 by Eisai Inc.. Recruitment status was Active, not recruiting
NCT00124527Thyroid CancerPhase 22021-06-16Eisai Inc.Completed
NCT00003441Colorectal CancerPhase 22018-10-25M.D. Anderson Cancer CenterCompleted
Appearance
Soild powder
Purity
≥95%
Shipping
Room temperature
Current Developer
MGI PHARMA
1. Natural sesquiterpenoids
Braulio M. Fraga. Nat. Prod. Rep., 2004, 21, 669–693
A formal synthesis of7-protoilludene has been described. The distribution of ptaquiloside has been studied in four Danish bracken populations in order to evaluate the transfer of this carcinogenic sesquiterpene from ferns to the soil. An approach to the synthesis of pteridanone, the aglycone of the glucoside pteridanoside, has been reported. Studies on the structure–activity relationship of illudin analogues possessing a spiro-cyclobutane ring have been carried out. Illudin S has been identified as the sole antiviral compound present in an extract of mature fruiting bodies ofOmphalotus illudens. A library of forty-nine illudinoids has been preparedvia a three-step synthesis and tested against three cancer cell lines. The reaction of the antitumour agent irofulven with zinc and acetic acid led to a series of compounds, which present a more reduced toxicity to human leukaemia than irofulven. Synthetic studies towards the framework construction of the fomannosane sesquiterpene illudosin have been reported.
2. Recent advances in the use of temporary silicon tethers in metal-mediated reactions
Sonia Bracegirdle and Edward A. Anderson*. Chem. Soc. Rev.,2010,39, 4114–4129
Finally, an equally impressive example of enyne RCM in total synthesis is illustrated by the Movassaghi group’s preparation of (-)-acylfulvene (51, Scheme 10) and (-)-irofulven, two members of the cytotoxic illudin family. Preparation of the disiloxane52was readily achievedviaunion of an appropriate alkyne and aldehyde, followed by silylation. This substrate is designed with great care, as TST ring-closing enyne metathesis must be achieved in the presence of an additional ‘spectator’ trisubstituted alkene, and for this the phenyl substituent proved crucial as a protecting group. Thus, initiation of the cascade cyclisation at the mono-substituted alkene was followed by dienyne RCM, terminating on the 1,1-disubstituted alkene, which afforded the 7,6-bicycle53in an outstanding 79% yield; notably, the use of less bulky or non-conjugated blocking groups on the trisubstituted alkene led to competing metathesis side-reactions.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Services

Products

Resource

Send Inquiry

Verification code
Inquiry Basket